Categories: News

Cytek Biosciences to Report Second Quarter 2023 Financial Results on August 8, 2023

FREMONT, Calif., July 20, 2023 (GLOBE NEWSWIRE) — Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced it will report financial results for the second quarter 2023 after market close on Tuesday, August 8th, 2023. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.

Live audio of the webcast will be available on the “Investors” section of the company website at investors.cytekbio.com.

About Cytek Biosciences
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP™) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s FSP platform includes its core instruments, the Aurora and Northern Lights™ systems; its cell sorter, the Aurora CS; the flow cytometer and imaging products under the Amnis® and Guava® brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com.

Other than Cytek’s Northern Lights CLC system and certain reagents for use therewith, which are available for clinical use in countries where the regulatory approval has been obtained from the local regulatory authorities, including China and the European Union, Cytek’s products are for research use only and not for use in diagnostic procedures. Please contact your local sales representatives for the status of local regulatory approval.

Cytek, Full Spectrum Profiling, FSP, Northern Lights, Amnis and Guava are trademarks of Cytek Biosciences, Inc.

In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and corporate Twitter account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek’s website, LinkedIn page, and Twitter account in addition to following its SEC filings, news releases, public conference calls and webcasts.

Media Contact:
Stephanie Olsen
Lages & Associates
(949) 453-8080
stephanie@lages.com 

Investor Relations Contact:
Paul D. Goodson
Head of Investor Relations
pgoodson@cytekbio.com

Staff

Recent Posts

The Unsuspected Effects of Extreme Heat on Quebec’s Healthcare System

An INRS team is studying the health burden of heat and its impact on the…

50 mins ago

Gareth Williams appointed CEO of Bionical Health

WILLINGTON, England, June 19, 2024 /PRNewswire/ -- Bionical Solutions, a leading provider of technology enabled…

50 mins ago

DNA Health & Wellness, the MENA Regions’ Largest Health Optimisation and Longevity Clinic Group, is Set to Expand into Abu Dhabi

With five pioneering & established clinics in Dubai, the new state-of-the-art clinic will open in…

50 mins ago

Tang Prize in Biopharmaceutical Science Honoring Three Scientists

TAIPEI, June 19, 2024 /PRNewswire/ -- In a continuing series of laureate announcements, the Tang Prize…

50 mins ago

Bioz and DENSsolutions Partner to Bring Real-Time Product Citation Data to DENSsolutions’ Researchers

PALO ALTO, CA / ACCESSWIRE / June 19, 2024 / Bioz, Inc., a leading AI…

50 mins ago